Hemodynamic, hormonal, and renal effects of (pro)renin receptor blockade in experimental heart failure

Circulation: Heart Failure

Volumn 5, Issue 5, 2012, Pages 645-652

  Rademaker, Miriam T ^a   Yandle, Tim G ^a   Ellmers, Leigh J ^a   Charles, Christopher J ^a   Gary Nicholls, M ^a   Mark Richards, A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

(Pro)renin receptor; Angiotensin II; Heart failure; Hemodynamics; Renin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; CATECHOLAMINE; CREATININE; ENDOTHELIN 1; PRORENIN RECEPTOR; PRORENIN RECEPTOR ANTAGONIST; RECEPTOR BLOCKING AGENT; RENIN; SODIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; ENZYME BLOOD LEVEL; FEMALE; HEART FAILURE; HEART LEFT ATRIUM PRESSURE; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART VENTRICLE PACING; HEMATOCRIT; HEMODYNAMICS; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; SODIUM BLOOD LEVEL; VASCULAR RESISTANCE;

ANIMALS; ARTERIAL PRESSURE; ATRIAL FUNCTION, LEFT; ATRIAL PRESSURE; BIOLOGICAL MARKERS; CARDIAC OUTPUT; CARDIAC PACING, ARTIFICIAL; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART FAILURE; HEMODYNAMICS; HORMONES; KIDNEY; MYOCARDIAL CONTRACTION; NATRIURESIS; OLIGOPEPTIDES; RECEPTORS, CELL SURFACE; RENIN-ANGIOTENSIN SYSTEM; SHEEP; TIME FACTORS; VASCULAR RESISTANCE;

EID: 84868658665     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.112.967059     Document Type: Article

References (33)

1. Nicholls MG, Richards AM, Agarwal M. The importance of the renin-angiotensin system in cardiovascular disease. J Hum Hypertens. 1998;12:295-299. (Pubitemid 28274359)
2. SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl J Med. 1991;325:293-302.
3. Sealey JE, Catanzaro DF, Lavin TN, Gahnem F, Pitarresi T, Hu LF, Laragh JH. Specific prorenin/renin binding (ProBP). Identification and characterization of a novel membrane site. Am J Hypertens. 1996;9:491-502.
4. Schefe JH, Neumann C, Goebel M, Danser J, Kirsch S, Gust R, Kintscher U, Unger T, Funke-Kaiser H. Prorenin engages the (pro) renin receptor like renin and both ligand activities are unopposed by aliskiren. J Hyper-tens. 2008;26:1787-1794.
5. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109:1417-1427. (Pubitemid 34596167)
6. Melnyk RA, Tam J, Boie Y, Kennedy BP, Percival MD. Renin and prorenin activate pathways implicated in organ damage in human mesangial cells independent of angiotensin II production. Am J Nephrol. 2009;30:232-243.
7. He M, Zhang L, Shao Y, Wang X, Huang Y, Yao T, Lu L. Inhibition of renin/prorenin receptor attenuated mesangial cell proliferation and reduced associated fibrotic factor release. Eur J Pharmacol. 2009;606:155-161.
8. Burcklé CA, Jan Danser AH, Müller DN, Garrelds IM, Gasc JM, Pop-ova E, Plehm R, Peters J, Bader M, Nguyen G. Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension. 2006;47:552-556. (Pubitemid 43843874)
9. Véniant M, Ménard J, Bruneval P, Morley S, Gonzales MF, Mullins J. Vascular damage without hypertension in transgenic rats expressing pro-renin exclusively in the liver. J Clin Invest. 1996;98:1966-1970. (Pubitemid 26376283)
10. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Suzuki F, Nakagawa T, Nishiyama A, Inagami T, Hayashi M. Nonproteolytic activation of pro-renin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension. 2006;47:894-900. (Pubitemid 44297561)
11. Danser AH, van Kesteren CA, Bax WA, Tavenier M, Derkx FH, Saxena PR, Schalekamp MA. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for re-nin binding. Circulation. 1997;96:220-226. (Pubitemid 27298424)
12. Hirose T, Mori N, Totsune K, Morimoto R, Maejima T, Kawamura T, Metoki H, Asayama K, Kikuya M, Ohkubo T, Kohzuki M, Taka-hashi K, Imai Y. Gene expression of (pro) renin receptor is upregulated in hearts and kidneys of rats with congestive heart failure. Peptides. 2009;30:2316-2322.
13. Susic D, Zhou X, Frohlich ED, Lippton H, Knight M. Cardiovascular effects of prorenin blockade in genetically spontaneously hypertensive rats on normal and high-salt diet. Am J Physiol Heart Circ Physiol. 2008;295:H1117-H1121.
14. Muller DN, Klanke B, Fibrot S, Cordasic N, Hartner A, Schmieder RE, Luft FC, Hilgers KF. (Pro) renin receptor peptide inhibitor "handle-region" peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. Hypertension. 2008;51:676-681. (Pubitemid 351301520)
15. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AH, Ishida Y, Ina-gami T, Saruta T. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest. 2004;114:1128-1135. (Pubitemid 39578702)
16. Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, Sakoda M, Nabi AH, Nishiyama A, Sugaya T, Hayashi M, Inagami T. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol. 2006;17:1950-1961. (Pubitemid 44036179)
17. Takahashi H, Ichihara A, Kaneshiro Y, Inomata K, Sakoda M, Takemitsu T, Nishiyama A, Itoh H. Regression of nephropathy developed in diabetes by (Pro) renin receptor blockade. J Am Soc Nephrol. 2007;18:2054-2061. (Pubitemid 47041071)
18. Seki Y, Ichihara A, Mizuguchi Y, Sakoda M, Kurauchi-Mito A, Narita T, Kinouchi K, Bokuda K, Itoh H. Add-on blockade of (pro) renin receptor in imidapril-treated diabetic SHRsp. Front Biosci (Elite Ed). 2010;2:972-979.
19. Fitzpatrick MA, Nicholls MG, Espiner EA, Ikram H, Bagshaw P, Yandle TG. Neurohumoral changes during onset and offset of ovine heart failure: role of ANP. Am J Physiol. 1989;256(4 Pt 2):H1052-H1059.
20. Rademaker MT, Charles CJ, Richards AM. Urocortin 1 administration from onset of rapid left ventricular pacing represses progression to overt heart failure. Am J Physiol Heart Circ Physiol. 2007;293:H1536-H1544. (Pubitemid 47367198)
21. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Nicholls MG, Richards AM. Natriuretic peptide responses to acute and chronic ventricular pacing in sheep. Am J Physiol. 1996;270(2 Pt 2):H594-H602.
22. Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T. Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II. J Cardiovasc Pharmacol. 1998;31:116-125. (Pubitemid 28027907)
23. Rademaker MT, Charles CJ, Cooper GJ, Coy DH, Espiner EA, Lewis LK, Nicholls MG, Richards AM. Combined angiotensin-converting enzyme inhibition and adrenomedullin in an ovine model of heart failure. Clin Sci. 2002;102:653-660. (Pubitemid 34620897)
24. Rademaker MT, Charles CJ, Nicholls MG, Richards AM. Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure. Clin Sci. 2008;114:635-642. (Pubitemid 351589062)
25. Fitzpatrick MA, Rademaker MT, Charles CJ, Yandle TG, Espiner EA, Ikram H. Angiotensin II receptor antagonism in ovine heart failure: acute hemodynamic, hormonal, and renal effects. Am J Physiol. 1992;263(1 Pt 2):H250-H256.
26. Nguyen G. Renin/prorenin receptors. Kidney Int. 2006;69:1503-1506.
27. Hirose T, Hashimoto M, Totsune K, Metoki H, Asayama K, Kikuya M, Sugimoto K, Katsuya T, Ohkubo T, Hashimoto J, Rakugi H, Takahashi K, Imai Y. Association of (pro) renin receptor gene polymorphism with blood pressure in Japanese men: the Ohasama study. Am J Hypertens. 2009;22:294-299.
28. Ellmers L, Carter E, Scott NJA, Richards AM, Cameron VA, Rade-maker MT. Urocortin 2 treatment reduces genes involved in cardiac remodelling in an ovine model of heart failure. Eur Heart J. 2009;30(Suppl):288.
29. Salas MA, Vila-Petroff MG, Palomeque J, Aiello EA, Mattiazzi A. Positive inotropic and negative lusitropic effect of angiotensin II: in-tracellular mechanisms and second messengers. J Mol Cell Cardiol. 2001;33:1957-1971. (Pubitemid 33097275)
30. Lambert C. Mechanisms of angiotensin II chronotropic effect in anaesthetized dogs. Br J Pharmacol. 1995;115:795-800.
31. Reudelhuber TL. Prorenin, Renin, and their receptor: moving targets. Hypertension. 2010;55:1071-1074.
32. Nurun NA, Uddin NM, Nakagawa T, Iwata H, Ichihara A, Inagami T, Suzuki F. Role of "handle" region of prorenin prosegment in the non-proteolytic activation of prorenin by binding to membrane anchored (pro) renin receptor. Front Biosci. 2007;12:4810-4817.
33. Kaneshiro Y, Ichihara A, Sakoda M, Takemitsu T, Nabi AH, Uddin MN, Nakagawa T, Nishiyama A, Suzuki F, Inagami T, Itoh H. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro) renin receptor-transgenic rats. J Am Soc Nephrol. 2007;18:1789-1795. (Pubitemid 46870315)